The Pharma Data

DECEMBER 16, 2020

Evotec and Bristol Myers Squibb (the successor in interest to Celgene ) initiated their long-term strategic drug discovery and development partnership in the field of targeted protein degradation in 2018 with the goal to identify novel drug targets.

Targeted Protein Degradation 40

Targeted Protein Degradation Bioinformatics Disease Production 40

Drug Discovery World

OCTOBER 6, 2022

This growth is due to factors including a rise in speciality medicines, an increase in lifestyle-driven diseases and a growing population 1. France, Switzerland, and the United Kingdom have seen the fastest growth, accounting for 63% of the biotechs founded between 2018 and 2020.” Valued at $14.8 until 2030. Hotspots . References: .

Targeted Protein Degradation 130

Targeted Protein Degradation Drugs Pharma Companies Marketing 130

Drug Target Review

JULY 5, 2024

Since brain organoids can be derived from either diseased or healthy patients, they can recapitulate human (patho)physiology making them a better choice compared to mammalian cell systems that often fail to recapitulate the human phenotype. 15(9):700-706 (2018) [link] Deshmukh V, et al. 12(3) (2023). link] Madhavan M, et al.

Targeted Protein Degradation 58

Targeted Protein Degradation Drugs FDA Approval Disease 58

The Pharma Data

JULY 22, 2021

(NYSE: PFE) today announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The estrogen receptor is a well-known disease driver in most breast cancers. Chief Executive Officer at Arvinas.

Targeted Protein Degradation 52

Targeted Protein Degradation Therapies Clinical Trials Treatment 52

Drug Discovery World

JANUARY 3, 2023

Targeted protein degradation and related modalities. A new modality where DEL screening has had particular impact is targeted protein degradation (TPD), a modality that has generated rapidly increasing interest in recent years. SLAS Discovery (2018). Brown DG, et al. Disch JS, et al. link] .

DNA 130

DNA Targeted Protein Degradation Small Molecule Pharma Companies 130

Drug Discovery World

MAY 30, 2023

These targeted cytokines are selectively removed with the intention of neutralising the cancer’s ability to block a patient’s natural immune defence mechanisms, which are significantly compromised in late-stage, metastatic disease. This potentially re-energises the immune system to fight cancers.”

Research 130

Research Targeted Protein Degradation Drugs RNA 130

Drug Target Review

OCTOBER 4, 2023

Antibody-drug conjugates (ADCs) have been a groundbreaking approach to cancer treatment with their ability to deliver cytotoxic drugs directly to diseased cells while sparing healthy tissues. This targeted delivery allows enhanced therapeutic efficacy while reducing the harmful side effects commonly associated with traditional chemotherapy.

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126